| Attribute | Value | [1] |
|---|---|---|
| Symbol | KIF4A | |
| Name | Kinesin Family Member 4A | |
| Chromosome | Xq13.1 | |
| NCBI Gene ID | 22937 | |
| UniProt ID | O95239 | |
| Protein Family | Kinesin-4 family | |
| Molecular Weight | ~140 kDa | |
| Expression | Brain (neurons), proliferating cells |
The KIF4A gene spans approximately 50 kb on chromosome Xq13.1 and consists of 23 exons. It encodes a protein of 1232 amino acids belonging to the kinesin-4 family, characterized by a long N-terminal motor domain, extended coiled-coil regions for dimerization and cargo binding, and a unique C-terminal domain. KIF4A is one of the largest kinesin family members, with structural features optimized for long-range transport in neurons [2].
Phylogenetic analysis reveals that KIF4A is highly conserved among mammals, with orthologs in mice, rats, and zebrafish. The gene has undergone specific duplication in primates, and the X-chromosomal location suggests potential sex-specific expression patterns. KIF4A shares the kinesin-4 family signature but has evolved unique neuronal functions distinct from its paralogs.
KIF4A is a member of the kinesin-4 family with distinctive structural features:
KIF4A exhibits several unique biochemical characteristics:
KIF4A undergoes several post-translational modifications:
KIF4A is a major axonal transport motor essential for neuronal function [3]:
In non-neuronal cells, KIF4A plays roles in mitosis:
In neurons, KIF4A is particularly important for:
KIF4A dysfunction contributes to AD pathogenesis through multiple mechanisms:
Amyloid-beta effects: Amyloid-beta oligomers disrupt axonal transport by inhibiting kinesin motors, including KIF4A. Studies show that Aβ directly interferes with motor function, leading to impaired delivery of synaptic proteins and subsequent synaptic loss [7].
Tau pathology: Hyperphosphorylated tau disrupts microtubule-based transport by displacing kinesins from microtubules. KIF4A is particularly vulnerable because it competes directly with tau for microtubule binding sites. The displacement of KIF4A from microtubules contributes to the characteristic axonal transport deficits in AD [8][9].
Axonal transport defects: Early axonal transport disruption is a hallmark of AD:
Synaptic dysfunction: KIF4A transport deficits lead to:
KIF4A plays several roles in PD pathogenesis:
Alpha-synuclein toxicity: Alpha-synuclein aggregates disrupt axonal transport through multiple mechanisms:
KIF4A dysfunction contributes to the characteristic axonal transport deficits observed in PD models, particularly in dopaminergic neurons [10][11].
Dopaminergic neuron vulnerability: The unique vulnerability of dopaminergic neurons in PD relates to their high transport demands and long axons. KIF4A is crucial for maintaining synaptic function in these neurons, and transport deficits contribute to degeneration.
LRRK2 connections: LRRK2 mutations cause familial PD. LRRK2 phosphorylates kinesin motors, including KIF4A. This phosphorylation regulates motor activity, and LRRK2 mutations disrupt this regulatory mechanism, leading to axonal transport deficits.
Axonal transport defects are central to ALS pathogenesis:
TDP-43 pathology: TDP-43 aggregates disrupt axonal transport by affecting kinesin function. KIF4A transport is impaired in TDP-43 models, contributing to motor neuron degeneration [12].
Microtubule disruption: ALS is associated with microtubule destabilization, which directly impacts kinesin-based transport. KIF4A's dependence on microtubule tracks makes it vulnerable.
Motor neuron-specific vulnerabilities: Motor neurons have extremely long axons with exceptionally high transport demands. KIF4A dysfunction disproportionately affects these cells, leading to axonal degeneration and eventual cell death.
KIF4A dysfunction contributes to HD pathogenesis:
Mutant huntingtin effects: Mutant huntingtin protein disrupts axonal transport through multiple mechanisms:
KIF4A-mediated transport is impaired in HD models, contributing to the characteristic axonal pathology [13].
Cargo-specific deficits: Different cargoes are differentially affected in HD, with synaptic vesicle precursors being particularly vulnerable due to their dependence on KIF4A.
Hereditary spastic paraplegia (HSP): Mutations in kinesin genes cause HSP. While KIF4A mutations are not a common cause, the importance of kinesin-mediated transport in HSP pathogenesis is well-established [14].
Frontotemporal dementia (FTD): TDP-43 pathology in FTD disrupts axonal transport, and KIF4A dysfunction may contribute to the characteristic neurodegeneration.
Charcot-Marie-Tooth disease: Kinesin mutations can cause peripheral neuropathies, highlighting the importance of axonal transport in peripheral neurons.
KIF4A interacts with several proteins relevant to neurodegeneration:
KIF4A expression changes may serve as biomarkers:
KIF4A represents a potential therapeutic target:
KIF4A dysfunction leads to axonal transport impairment through multiple mechanisms:
Deficits in KIF4A-mediated transport lead to:
Transport defects contribute to axonal degeneration through:
While KIF4A is not a direct AD risk gene, the kinesin family is implicated in AD pathogenesis through:
Kinesin dysfunction is a feature of PD:
Rare variants in kinesin genes have been identified in ALS patients:
Several strategies target kinesin-mediated transport:
KIF4A-targeted approaches may be combined with:
KIF4A is connected to several key pathways:
Related genes and proteins:
Miki et al. Kinesin proteins in the mammalian central nervous system. 2001. ↩︎
Hirokawa et al. Neuronal polarity and axonal transport. 2010. ↩︎
Kim et al. KIF4A mediates axonal transport of synaptic vesicle precursors. 2008. ↩︎
Konishi et al. KIF4A regulates chromosome alignment and spindle assembly. 2004. ↩︎
Yu et al. KIF4A is required for chromosome congression. 2005. ↩︎
Kavita et al. Kinesin dysfunction in Alzheimer's disease. 2021. ↩︎
Xia et al. Kinesin and tau pathology in Alzheimer's disease. 2003. ↩︎
Chen et al. Tau pathology disrupts axonal transport. 2019. ↩︎
Yuan et al. Kinesin dysfunction in Parkinson's disease models. 2015. ↩︎
Cheng et al. Kinesin family alterations in Parkinson's disease. 2022. ↩︎
Edwards et al. Microtubule-based transport in ALS. 2023. ↩︎
Lopez et al. Axonal transport defects in Huntington's disease. 2019. ↩︎
Matsuzaki et al. Kinesin-1 mutations cause hereditary spastic paraplegia. 2018. ↩︎